Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.08

-2.9%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (23487)	4/18/2007 10:32:39 AM
From: NeuroInvestment	Read Replies (1) of 52153

Peter, I'm sorry if I contributed to the process of 'driving you crazy.' But with all due respect to the nuanced improvements offered by later triptans, or Lexapro over some earlier SSRI's, or--actually I can't come up with any incremental benefits offered by later atypical antipsychotics (not including mechanistic variants like Abilify) or cholinesterase inhibitors: from a pharmacoeconomic point of view, when you think of the billions that went into developing the later entrants, I can't avoid the conclusion that the money could have been better spent elsewhere. As a clinician, given patient variability, I certainly like the concept of having as many choices on the menu as possible. But I'd be even happier to have an option that effectively addresses the cognitive deficits of schizophrenia, or the disease process of Alzheimer's, etc. etc....It's hard for me to avoid the conclusion that the diversion of resources--both at the Pharma and FDA ends--to nuanced improvements has slowed the pace of progress towards more fundamentally advanced generations of therapeutics. Harry NeuroInvestment

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next